Arrowhead Pharmaceuticals Inc (ARWR) - News Archive

In a major announcement on August 8, 2024, Arrowhead Pharmaceuticals (NASDAQ: ARWR) revealed plans to host a highly anticipated webcast and conference call at 4:30 p.m. ET. This event aims to provide investors and stake...

Title : Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes TrialArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the initiation of a Phase 3 cardiovascula...

Arrowhead Pharmaceuticals Demonstrates Promising Results in Multiple Clinical Trials for Treatment of Genetic DiseasesArrowhead Pharmaceuticals, a leading biopharmaceutical company, has recently reported successful topl...

Arrowhead Pharmaceuticals, a California-based biopharmaceutical company, has recently presented new clinical data on two of its investigational RNAi-based medicines that show promising results in the treatment of mixed...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), an innovative biopharmaceutical company focusing on RNA interference (RNAi) therapies, continues to make significant strides in the treatment of cardiovascular and metabol...

Arrowhead Pharmaceuticals Presents Promising Clinical Data on ARO-RAGE for Asthma TreatmentArrowhead Pharmaceuticals recently shared interim clinical data on their investigational RNAi-based medicine, ARO-RAGE, for the...

In a breakthrough that marks a significant leap in the development of novel therapeutics, Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) recently received a colossal $50 million milestone payment from Royalty Pharma plc...

Arrowhead Pharmaceuticals, a leading biopharmaceutical company, is set to make waves in the scientific community with its upcoming 2024 Summer Series of R&D webinars. The series will serve as a platform to highlight Arr...

The clinical trial, registered under the identifier NCT06209177, intends to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ARO-CFB in its participants. The study will inclusively assess the...

Arrowhead Pharmaceuticals, a leading biopharmaceutical company, has recently launched an Expanded Access Program (EAP) to provide access to investigational plozasiran for patients suffering from familial chylomicronemia...

Arrowhead Pharmaceuticals, a biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, has made significant progress in its efforts to develop effective treatments for various types of muscular dys...

Arrowhead Pharmaceuticals, a California-based biopharmaceutical company, has successfully closed an underwritten registered offering, raising gross proceeds of $450.0 million. The offering involved the sale of 15,790,00...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), a leading biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, recently disclosed the successful pricing of an underwritten registered offering...

Arrowhead Pharmaceuticals Announces Inducement Grants to New Employees under NASDAQ Listing Rule 5635(c)(4)Facts: Arrowhead Pharmaceuticals Inc. recently revealed its decision to offer inducement grants to 32 new employ...

Arrowhead Pharmaceuticals, a renowned biopharmaceutical company, has taken a significant step forward in its quest for a potential treatment for complement mediated kidney disease. The company recently filed for regulat...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has made significant strides in its mission to combat type 1 Myotonic Dystrophy (DM1), a prevalent adult-onset muscular dystrophy. The innovative biopharmaceutical company h...

Arrowhead Pharmaceuticals Inc. will be presenting new Phase 2 clinical data for its cardiometabolic pipeline at the upcoming American Heart Association (AHA) Scientific Sessions 2023. The studies being showcased include...